Functional mutations in TP53 are of considerable significance in neuro-oncology as aberrant p53 expression in glioblastoma multiforme (GBM), a terminal brain tumor, has been associated with worse patient outcomes and decreased chemosensitivity to temozolomide [4, 5]. Here, TP53 is linked to glioblastoma.